Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. furnished a regulatory disclosure stating that it issued a press release providing its full-year 2026 financial guidance and revising its full-year 2025 revenue guidance.
The company reaffirmed all other components of its full-year 2025 financial guidance in the same press release, which is attached as an exhibit to the disclosure.
Pfizer Inc. Chairman and CEO Albert Bourla reported an insider equity transaction involving company-linked deferred compensation. On 11/28/2025, he acquired 23 Phantom Stock Units SSP, each representing one phantom share of Pfizer common stock at a reference price of $25.74 per unit. Following this transaction, he beneficially owns 743,115 phantom stock units.
The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and may be moved by him into an alternative investment account at any time. The filing is made by one reporting person in his roles as both director and Chairman & CEO.
Pfizer Inc. completed a multi-tranche public notes offering, issuing $500,000,000 of Floating Rate Notes due 2027 and several series of fixed-rate notes with maturities from 2027 to 2065. The fixed-rate tranches include $1,000,000,000 of 3.875% Notes due 2027, $1,000,000,000 of 4.200% Notes due 2030, $1,250,000,000 of 4.500% Notes due 2032, $1,250,000,000 of 4.875% Notes due 2035, $500,000,000 of 5.600% Notes due 2055 and $500,000,000 of 5.700% Notes due 2065. The notes were issued under Pfizer’s existing shelf registration statement and an indenture with The Bank of New York Mellon, with Citigroup, Deutsche Bank, J.P. Morgan and Mizuho acting as lead underwriters.
Pfizer Inc. is issuing $500 million of floating-rate notes due 2027 and $5.5 billion of fixed-rate notes maturing between 2027 and 2065. The fixed-rate tranches carry coupons of 3.875% (2027), 4.200% (2030), 4.500% (2032), 4.875% (2035), 5.600% (2055) and 5.700% (2065), with interest paid semi-annually, while the floating-rate notes pay quarterly interest at Compounded SOFR plus 0.500%. The notes are unsecured, unsubordinated obligations ranking equally with Pfizer’s other unsubordinated debt and have no sinking fund.
Pfizer expects net proceeds of approximately $5,966,010,000 after underwriting discounts, to be used for general corporate purposes, including funding the acquisition of Metsera and refinancing existing indebtedness. Fixed-rate notes are callable at Pfizer’s option (subject to make‑whole and par call features), while the floating-rate notes are not redeemable before maturity. The notes will not be listed on any securities exchange, and Pfizer highlights risks around subordination to secured and subsidiary debt, benchmark rate reform and SOFR-related volatility for the floating‑rate series.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 24 phantom stock units linked to Pfizer common stock on 11/14/2025 at $25.06 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after his separation from service, rather than in actual shares. The units may be transferred by him into an alternative investment account at any time. Following this transaction, he beneficially owned 743,548 derivative securities in the form of these phantom stock units, held in direct form.
Pfizer Inc. filed a Form 13F reporting holdings: 24 instrument entries with a total value of $437,450,705. The report was signed on 11-13-2025. This filing lists institutional equity positions held by the manager as of the reporting period and summarizes aggregate value and count of entries.
Pfizer Inc. completed its acquisition of Metsera, Inc. The deal converted each Metsera share into $65.60 in cash at closing, representing an enterprise value of approximately $7.0 billion, plus a non-transferable contingent value right (CVR) worth up to $20.65 per share upon achieving specified milestones.
The CVR includes three potential cash payments tied to Metsera’s GLP‑1 programs:
- $4.60 per share upon initiation of the Phase 3 clinical trial of the MET-097i (GLP-1 receptor antagonist) + MET-233i (amylin analog) combination.
- $6.40 per share upon FDA approval of monthly MET-097i monotherapy.
- $9.65 per share upon FDA approval of monthly MET-097i + MET-233i combination.
Pfizer Inc. filed its Q3 2025 report, showing lower quarterly results versus last year and executing major portfolio moves. Total revenues were $16,654 million, down from $17,702 million in Q3 2024, and diluted EPS was $0.62 versus $0.78. Year-to-date, net income attributable to common shareholders was $9,419 million, up from $7,621 million, aided by a negative effective tax rate and portfolio actions.
The company recorded a $1,350 million charge in Acquired in-process R&D tied to an exclusive global (ex-China) in-licensing of SSGJ-707 from 3SBio, which also included a $100 million equity investment and up to $4,800 million in potential milestones. Pfizer also entered R&D funding arrangements with Abingworth (up to $200 million through 2027) and Blackstone (up to $326 million through 2028), with approval- and sales-based milestone payment structures after potential approvals.
Pfizer continued multi-year cost programs: the Realigning Our Cost Base Program and the Manufacturing Optimization Program. Cumulative costs through September 28, 2025 reached $3.7 billion for the realignment and $1.0 billion for manufacturing optimization. Cash from investing included $6,311 million of proceeds from sales of the remaining Haleon stake. Shares outstanding were 5,685,707,552 as of October 29, 2025.
Pfizer Inc. filed an 8-K announcing its third-quarter 2025 financial results. The company furnished a press release as Exhibit 99 dated November 4, 2025, detailing the quarter’s performance. The information under Item 2.02 (Results of Operations and Financial Condition) is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings except by specific reference. An Inline XBRL cover page file is also included as Exhibit 104.
Pfizer Inc. (PFE) insider activity: Chairman & CEO and Director Albert Bourla reported the acquisition of 24 phantom stock units on 10/31/2025 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
The filing lists a price of $24.65 for the derivative security and shows 731,108 derivative securities beneficially owned following the transaction, held as direct ownership. These phantom stock units represent the value of one share each and are settled in cash after the reporting person’s separation from service; they may be moved into an alternative investment account at any time.